Eli Lilly and Co (LLY) has declared a dividend of $1.50 per share, payable to shareholders of record. This quarterly dividend reflects the company’s commitment to providing regular income to its investors.
The ex-dividend date is set for November 13, 2025. Investors must own shares before this date to qualify for the dividend; those purchasing on or after will not be entitled to this payment. Eligible shareholders will receive the dividend on December 9, 2025.
Currently, Eli Lilly's dividend yield stands at 0.65%, calculated based on the annual dividend income relative to the stock price. The company, headquartered in Indianapolis, Indiana, engages in the discovery, development, manufacture, and sale of pharmaceutical products. With a market capitalization of $886.2 billion, it employs approximately 47,000 individuals.
Eli Lilly's diverse product portfolio includes treatments for cardiometabolic health, oncology, immunology, and neuroscience. The company is also advancing radiopharmaceutical developments through its subsidiary, POINT Biopharma Global Inc.
Investors typically assess a company's dividend history, payout ratio, and overall financial health to gauge the sustainability of such payments. The announcement highlights Eli Lilly's ongoing strategy to return value to shareholders, although dividends are subject to change based on business performance and management decisions.
Upcoming earnings are scheduled for August 4, 2026, with EPS estimated at $7.70 and revenue expected to reach $17.9 billion.